LGVN News and Press, Longeveron Inc. From 04/12/21

New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, was recently the focus of coverage by leading fina...

Longeveron, Inc. (LGVN) Q4 2020 Earnings Conference Call March 30, 2021 8:30 AM ET Company Participants Natalya Rudman – Senior Vice President-Crescendo Communications Geoff Green – Chief Executive Officer Joshua Hare – Co-Founder, Chief Science Officer and Chairman James...

Longeveron shares up ([[LGVN]] +11.0%) after the company posted fourth-quarter results and provided a business update listing out its achievements during the period. Total revenue for the quarter fell 33% to $1.2M year-over-year, as the company dealt with a fall in grant revenue during t...

Longeveron (LGVN): Q4 Net loss of $1.4MRevenue of $1.2M (-33.3% Y/Y)Press Release For further details see: Longeveron reports Q4 results

MIAMI, March 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today reported its financial results for the quarter and full...

MIAMI, March 26, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced it will host a conference call at 8:30 a....

MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Gree...

MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the underwriters of its previousl...

Gainers: NLS Pharmaceutics NLSP +111%, Entera Bio ENTX +75%, Seelos Therapeutics SEEL +34%, Regulus Therapeutics (RGLS) +27%, Rafael (RFL) +27%.Losers: Marker Therapeutics MRKR -28%, Timber Pharmaceuticals (TMBR) -21%, Evoke Pharma EVOK&#...

Marker Therapeutics MRKR -24% after prices stock offering.Timber Pharmaceuticals (TMBR) -25%.Evoke Pharma EVOK -24% on Q4 earnings release.FinVolution (FINV) -15%.Poshmark POSH -15% on Q4 earnings release; after Q1 revenue guidance falls short.AMMO POWW ...